OMC
LENZ

Oasis Management Company’s LENZ Therapeutics LENZ Stock Holding History

Oasis Management Company’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-36,443
Closed -$847K – 114
2022
Q4 		$847K Hold
36,443
– – 0.17% 53
2022
Q3 		$809K Hold
36,443
– – 0.14% 66
2022
Q2 		$702K Buy
+36,443
New +$812K 0.12% 69

Other funds holding LENZ

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 28.88% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Oasis Management Company's LENZ Position: Q1 2023 in Review

Oasis Management Company sold out of LENZ Therapeutics (LENZ) in Q1 2023, closing a stake of 36,443 shares — an estimated $847K sold.

Oasis Management Company first reported a position in LENZ in Q2 2022 and held it in 3 quarters. The position peaked at $847K in Q4 2022. 62 funds tracked by Wall St. Rank hold LENZ as of Q1 2023.

  • Oasis Management Company reported no remaining LENZ Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Oasis Management Company sold 36,443 LENZ Therapeutics shares in Q1 2023, an estimated $847K.
  • Oasis Management Company first reported a position in LENZ Therapeutics in Q2 2022 and held it in 3 quarters.
  • Oasis Management Company's LENZ Therapeutics position peaked at $847K in Q4 2022.
  • 62 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2023.

Based on Oasis Management Company's 13F filing for Q1 2023, filed 15 May 2023.